Results revealed widespread hypomethylation at the LAPTM4A promoter sites in glioma samples, with differential methylation levels observed across different subtypes, displaying a trend of decreasing methylation levels with increasing glioma grades. Here, LAPTM4A is linked to central nervous system cancer.